Aileron Therapeutics (ALRN) News Today → “Dollar Will Be Worth NOTHING” -Musk (From Crypto 101 Media) (Ad) Free ALRN Stock Alerts $3.85 -0.05 (-1.28%) (As of 05/16/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 16 at 9:11 AM | finanznachrichten.deAileron Therapeutics, Inc.: Aileron Therapeutics Reports First Quarter 2024 Financial Results and Business HighlightsMay 15 at 11:10 PM | msn.comALRN Stock Earnings: Aileron Therapeutics Reported Results for Q1 2024May 15 at 6:09 PM | tmcnet.comAileron Therapeutics Reports First Quarter 2024 Financial Results and Business HighlightsMay 15 at 5:13 PM | globenewswire.comAileron Therapeutics Reports First Quarter 2024 Financial Results and Business HighlightsMay 12, 2024 | americanbankingnews.comAileron Therapeutics, Inc. (NASDAQ:ALRN) Sees Large Increase in Short InterestMay 10, 2024 | marketbeat.comAileron Therapeutics, Inc. (NASDAQ:ALRN) Sees Significant Growth in Short InterestAileron Therapeutics, Inc. (NASDAQ:ALRN - Get Free Report) was the recipient of a significant growth in short interest in the month of April. As of April 30th, there was short interest totalling 135,900 shares, a growth of 213.1% from the April 15th total of 43,400 shares. Currently, 1.0% of the company's shares are sold short. Based on an average trading volume of 85,700 shares, the days-to-cover ratio is presently 1.6 days.May 6, 2024 | globenewswire.comAileron Therapeutics to Present at Two Upcoming Investor ConferencesMay 3, 2024 | seekingalpha.comALRN Aileron Therapeutics, Inc.May 3, 2024 | finance.yahoo.comAileron Therapeutics Announces Closing of Underwritten Registered Direct Offering of up to Approximately $40 MillionMay 3, 2024 | globenewswire.comAileron Therapeutics Announces Closing of Underwritten Registered Direct Offering of up to Approximately $40 MillionMay 2, 2024 | finance.yahoo.comAileron reports data from Cohort 1 of Phase Ib inhaled IPF treatment trialMay 2, 2024 | insidertrades.comInsider Selling: Aileron Therapeutics, Inc. (NASDAQ:ALRN) Major Shareholder Sells 10,746 Shares of StockMay 1, 2024 | marketbeat.comAileron Therapeutics, Inc. (NASDAQ:ALRN) Major Shareholder Sells $53,192.70 in StockAileron Therapeutics, Inc. (NASDAQ:ALRN - Get Free Report) major shareholder Of Texas/Texas Am I. University sold 10,746 shares of the company's stock in a transaction on Monday, April 29th. The shares were sold at an average price of $4.95, for a total value of $53,192.70. Following the completion of the transaction, the insider now owns 1,799,711 shares of the company's stock, valued at approximately $8,908,569.45. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Major shareholders that own at least 10% of a company's stock are required to disclose their transactions with the SEC.May 1, 2024 | globenewswire.comAileron Therapeutics Announces Pricing of Underwritten Registered Direct Offering Priced At-The-Market Under Nasdaq Rules of up to Approximately $40 MillionMay 1, 2024 | globenewswire.comAileron Therapeutics Announces Positive Data from Cohort 1 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)April 28, 2024 | marketbeat.comShort Interest in Aileron Therapeutics, Inc. (NASDAQ:ALRN) Rises By 22.9%Aileron Therapeutics, Inc. (NASDAQ:ALRN - Get Free Report) saw a significant increase in short interest in the month of April. As of April 15th, there was short interest totalling 43,400 shares, an increase of 22.9% from the March 31st total of 35,300 shares. Based on an average daily volume of 65,900 shares, the short-interest ratio is presently 0.7 days. Approximately 0.3% of the company's shares are sold short.April 18, 2024 | marketbeat.comTrading was temporarily halted for "ALRN" at 09:04 AM with a stated reason of "LULD pause."April 16, 2024 | investorplace.comALRN Stock Earnings: Aileron Therapeutics Reported Results for Q4 2023April 16, 2024 | finanznachrichten.deAileron Therapeutics, Inc.: Aileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateApril 15, 2024 | globenewswire.comAileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateMarch 12, 2024 | markets.businessinsider.comAileron Therapeutics CEO Manuel Aivado Steps Down; Names Brian Windsor ReplacementMarch 12, 2024 | globenewswire.comAileron Therapeutics Announces CEO TransitionFebruary 28, 2024 | marketbeat.comTrading was temporarily halted for "ALRN" at 09:02 AM with a stated reason of "LULD pause."February 15, 2024 | finance.yahoo.comAileron Therapeutics and Pulmonary Care Experts To Discuss the Potential Implications of LTI-03 for Idiopathic Pulmonary Fibrosis in Virtual Key Opinion Leader EventFebruary 15, 2024 | globenewswire.comAileron Therapeutics and Pulmonary Care Experts To Discuss the Potential Implications of LTI-03 for Idiopathic Pulmonary Fibrosis in Virtual Key Opinion Leader EventFebruary 1, 2024 | finance.yahoo.comAileron Therapeutics to Host Key Opinion Leader Event on February 15, 2024January 30, 2024 | msn.comAileron Therapeutics Announces Director Nomination DetailsJanuary 30, 2024 | msn.comAileron Therapeutics Announces 2024 Annual Meeting PlansJanuary 30, 2024 | marketbeat.comTrading was temporarily halted for "ALRN" at 09:01 AM with a stated reason of "LULD pause."December 27, 2023 | benzinga.comAileron Therapeutics Stock (NASDAQ:ALRN) Dividends: History, Yield and DatesDecember 15, 2023 | msn.comU.S. shares higher at close of trade; Dow Jones Industrial Average up 0.43%December 1, 2023 | realmoney.thestreet.comAileron Therapeutics upgraded to Buy from Neutral at LadenburgDecember 1, 2023 | realmoney.thestreet.comAileron Therapeutics upgraded to Buy at Ladenburg after Lung Therapeutics dealNovember 5, 2023 | benzinga.comAileron Therapeutics Director Awarded $6K Worth of Stock OptionsNovember 1, 2023 | msn.comAileron gains after all-stock deal to acquire Lung TherapeuticsOctober 31, 2023 | finance.yahoo.comAileron Therapeutics Announces Acquisition of Lung TherapeuticsApril 4, 2023 | finance.yahoo.comBears are Losing Control Over Aileron Therapeutics, Inc. (ALRN), Here's Why It's a 'Buy' NowMarch 22, 2023 | finance.yahoo.comAileron Therapeutics, Inc. (ALRN)March 14, 2023 | finance.yahoo.comAileron Therapeutics, Inc. (ALRN) Could Find a Support Soon, Here's Why You Should Buy the Stock NowMarch 3, 2023 | msn.comLooking Into Aileron Therapeutics's Recent Short InterestFebruary 23, 2023 | markets.businessinsider.comJonesTrading Keeps Their Hold Rating on Aileron Therapeutics (ALRN)February 22, 2023 | finance.yahoo.comCancer drugmaker down to 3 employees after trial failureFebruary 21, 2023 | msn.comU.S. stocks lower at close of trade; Dow Jones Industrial Average down 2.06%February 21, 2023 | seekingalpha.comAileron off 38% on plans to explore sale after setback for cancer candidateFebruary 21, 2023 | finance.yahoo.comAileron Therapeutics Shelves Development On Chemoprotection Agent, Shares FallFebruary 21, 2023 | markets.businessinsider.comAileron Terminates Phase 1b Breast Cancer Chemoprotection Trial Of ALRN-6924February 21, 2023 | marketwatch.comAileron Therapeutics Shares Slide to New Low on Lead Drug Failure >ALRNFebruary 21, 2023 | marketwatch.comAileron Exploring Options After ALRN-6924 Study Failure >ALRNFebruary 21, 2023 | marketbeat.comTrading was temporarily halted for "ALRN" at 08:02 AM with a stated reason of "News pending."January 17, 2023 | reuters.comalrn.a - | Stock Price & Latest News | Reuters Get Aileron Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ALRN and its competitors with MarketBeat's FREE daily newsletter. Email Address “Dollar Will Be Worth NOTHING” -Musk (Ad)Elon Musk just issued an urgent warning… Saying “The U.S. Dollar will be worth NOTHING…” As "stealth money printing" pushes the price of Bitcoin, Ethereum, XRP and crypto higher. Click here to claim your free seat ticket now. ALRN Media Mentions By Week ALRN Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ALRN News Sentiment▼0.830.55▲Average Medical News Sentiment ALRN News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ALRN Articles This Week▼91▲ALRN Articles Average Week Get Aileron Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ALRN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Viveon Health Acquisition News Lantern Pharma News Mural Oncology News AEON Biopharma News Landos Biopharma News Leap Therapeutics News Celularity News Eagle Pharmaceuticals News Carisma Therapeutics News Kronos Bio News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ALRN) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersGold Set to EXPLODE!Gold Safe ExchangeWith revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radarStocks NewsWhy Is Gold On a MASSIVE rally? Huge AlertsThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingCharles Payne Demystifies OptionsUnstoppable ProsperityBiden FINISHED On June 13th?Paradigm PressHow Biden has already won 2024Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aileron Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
